These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36852260)

  • 1. Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with
    Emiroglu S; Özkurt E; Cabıoglu N; Igci A; Saip P; Yazici H; Ozmen T; Ozmen V; Muslumanoglu M; Tukenmez M
    Breast Cancer (Dove Med Press); 2023; 15():163-173. PubMed ID: 36852260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Cao W; Xie Y; He Y; Li J; Wang T; Fan Z; Fan T; Ouyang T
    Breast Cancer Res Treat; 2019 Jun; 175(3):749-754. PubMed ID: 30895535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast-conserving therapy is safe both within
    Huang X; Cai XY; Liu JQ; Hao WW; Zhou YD; Wang X; Xu Y; Chen C; Lin Y; Wang CJ; Song Y; Sun Q
    Gland Surg; 2020 Jun; 9(3):775-787. PubMed ID: 32775268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncoplastic breast-conserving surgery for women with primary breast cancer.
    Nanda A; Hu J; Hodgkinson S; Ali S; Rainsbury R; Roy PG
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013658. PubMed ID: 34713449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    Maksimenko J; Rodrigues PP; Nakazawa-Miklaševiča M; Pinto D; Miklaševičs E; Trofimovičs G; Gardovskis J; Cardoso F; Cardoso MJ
    JMIR Form Res; 2022 Dec; 6(12):e37144. PubMed ID: 36580360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study.
    Chen X; Qian X; Xiao M; Zhang P
    Breast Cancer (Dove Med Press); 2023; 15():671-682. PubMed ID: 37692097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
    Shubeck S; Sevilimedu V; Berger E; Robson M; Heerdt AS; Pilewskie ML
    Ann Surg Oncol; 2022 Aug; 29(8):4706-4713. PubMed ID: 35585432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.
    Bernstein-Molho R; Laitman Y; Galper S; Jacobson G; Boursi B; Gal-Yam EN; Kaufman B; Friedman E; Kaidar-Person O
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1332-1340. PubMed ID: 33259931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
    Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
    Turner BC; Harrold E; Matloff E; Smith T; Gumbs AA; Beinfield M; Ward B; Skolnick M; Glazer PM; Thomas A; Haffty BG
    J Clin Oncol; 1999 Oct; 17(10):3017-24. PubMed ID: 10506595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in
    Vocka M; Zimovjanova M; Bielcikova Z; Tesarova P; Petruzelka L; Mateju M; Krizova L; Kotlas J; Soukupova J; Janatova M; Zemankova P; Kleiblova P; Novotny J; Konopasek B; Chodacka M; Brychta M; Sochor M; Smejkalova-Musilova D; Cmejlova V; Kozevnikovova R; Miskarova L; Argalacsova S; Stolarova L; Lhotova K; Borecka M; Kleibl Z
    Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
    Rosenberg SM; Sepucha K; Ruddy KJ; Tamimi RM; Gelber S; Meyer ME; Schapira L; Come SE; Borges VF; Golshan M; Winer EP; Partridge AH
    Ann Surg Oncol; 2015 Nov; 22(12):3809-15. PubMed ID: 25930247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis.
    Tomasello G; Gambini D; Petrelli F; Azzollini J; Arcanà C; Ghidini M; Peissel B; Manoukian S; Garrone O
    ESMO Open; 2022 Aug; 7(4):100531. PubMed ID: 35810556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.